Kedar R. Mahajan

Kedar R. Mahajan

Auto-generated profile, based on publicly available information

Kedar R. Mahajan

Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Neurosciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in WIREs Mechanisms of Disease
Verified
Journal Article
Open access
GMGabrielle M. Mey
Gabrielle M. Mey
KMKedar R. Mahajan
Kedar R. Mahajan
TDTara M. DeSilva
Tara M. DeSilva
Axonal loss in multiple sclerosis (MS) is a key component of disease progression and permanent neurologic disability. MS is a heterogeneous demyelinating and neurodegenerative disease of the central nervous system (CNS) with varying presentation, disease courses, and prognosis. Immunomodulatory therapies reduce the frequency and severity of inflammatory demyelinating events that are a hallmark of MS, but there is minimal therapy to treat progressive disease and there is no cure. Data from patients with MS, post‐mortem histological analysis, and animal models of demyelinating disease have elucidated patterns of MS pathogenesis and underlying mechanisms of neurodegeneration. MRI and molecular biomarkers have been proposed to identify predictors of neurodegeneration and risk factors for disease progression. Early signs of axonal dysfunction have come to light including impaired mitochondrial trafficking, structural axonal changes, and synaptic alterations. With sustained inflammation as well as impaired remyelination, axons succumb to degeneration contributing to CNS atrophy and worsening of disease. These studies highlight the role of chronic demyelination in the CNS in perpetuating axonal loss, and the difficulty in promoting remyelination and repair amidst persistent inflammatory insult. Regenerative and neuroprotective strategies are essential to overcome this barrier, with early intervention being critical to rescue axonal integrity and function. The clinical and basic research studies discussed in this review have set the stage for identifying key propagators of neurodegeneration in MS, leading the way for neuroprotective therapeutic development.This article is categorized under: Immune System Diseases > Molecular and Cellular Physiology Neurological Diseases > Molecular and Cellular Physiology

23 March 2021 in Brain
Verified
Journal Article
Open access
PDF file
DODaniel Ontaneda
Daniel Ontaneda
PRPraneeta C Raza
Praneeta C Raza
KMKedar R Mahajan
Kedar R Mahajan
DADouglas L Arnold
Douglas L Arnold
MDMichael G Dwyer
Michael G Dwyer
T(the North American Imaging in Multiple Sclerosis Cooperative (NAIMS)
the North American Imaging in Multiple Sclerosis Cooperative (NAIMS)
Although multiple sclerosis has traditionally been considered a white matter disease, extensive research documents the presence and importance of grey matter injury including cortical and deep regions. The deep grey matter exhibits a broad range of pathology and is uniquely suited to study the mechanisms and clinical relevance of tissue injury in multiple sclerosis using magnetic resonance techniques. Deep grey matter injury has been associated with clinical and cognitive disability. Recently, MRI characterization of deep grey matter properties, such as thalamic volume, have been tested as potential clinical trial end points associated with neurodegenerative aspects of multiple sclerosis. Given this emerging area of interest and its potential clinical trial relevance, the North American Imaging in Multiple Sclerosis (NAIMS) Cooperative held a workshop and reached consensus on imaging topics related to deep grey matter. Herein, we review current knowledge regarding deep grey matter injury in multiple sclerosis from an imaging perspective, including insights from histopathology, image acquisition and post-processing for deep grey matter. We discuss the clinical relevance of deep grey matter injury and specific regions of interest within the deep grey matter. We highlight unanswered questions and propose future directions, with the aim of focusing research priorities towards better methods, analysis, and interpretation of results.

10 August 2020 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
PDF file
BMBrandon P Moss
Brandon P Moss
KMKedar R Mahajan
Kedar R Mahajan
RBRobert A Bermel
Robert A Bermel
KHKelsey Hellisz
Kelsey Hellisz
LHLe H Hua
Le H Hua
KFKathryn C Fitzgerald
Kathryn C Fitzgerald
Background: People with multiple sclerosis (MS) may be at higher risk for complications from the 2019 coronavirus (COVID-19) pandemic due to use of immunomodulatory disease modifying therapies (DMTs) and greater need for medical services. Objectives: To evaluate risk factors for COVID-19 susceptibility and describe the pandemic’s impact on healthcare delivery. Methods: Surveys sent to MS patients at Cleveland Clinic, Johns Hopkins, and Vall d’Hebron-Centre d’Esclerosi Múltiple de Catalunya in April and May 2020 collected information about comorbidities, DMTs, exposures, COVID-19 testing/outcomes, health behaviors, and disruptions to MS care. Results: There were 3028/10,816 responders. Suspected or confirmed COVID-19 cases were more likely to have a known COVID-19 contact (odds ratio (OR): 4.38; 95% confidence interval (CI): 1.04, 18.54). In multivariable-adjusted models, people who were younger, had to work on site, had a lower education level, and resided in socioeconomically disadvantaged areas were less likely to follow social distancing guidelines. 4.4% reported changes to therapy plans, primarily delays in infusions, and 15.5% a disruption to rehabilitative services. Conclusion: Younger people with lower socioeconomic status required to work on site may be at higher exposure risk and are potential targets for educational intervention and work restrictions to limit exposure. Providers should be mindful of potential infusion delays and MS care disruption.

14 April 2020 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
KMKedar R. Mahajan
Kedar R. Mahajan
KNKunio Nakamura
Kunio Nakamura
JCJeffrey A. Cohen
Jeffrey A. Cohen
BTBruce D. Trapp
Bruce D. Trapp
DODaniel Ontaneda
Daniel Ontaneda

18 July 2019 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
PDF file
DDDimitrios Davalos
Dimitrios Davalos
KMKedar R Mahajan
Kedar R Mahajan
BTBruce D Trapp
Bruce D Trapp
Blood-brain barrier (BBB) disruption, perivascular inflammation, demyelination, and axonal damage are key histopathological hallmarks of multiple sclerosis (MS)1–3. The vast majority of MS lesions develop around disrupted blood vessels. This is often attributed to active inflammation and the infiltration of immune cells into the central nervous system (CNS). Indeed, evidence of BBB disruption by gadolinium enhancement on magnetic resonance imaging (MRI) constitutes the most reliable indication of active inflammatory MS lesions. However, increasing evidence highlights a more central role for the leakage of blood factors into the CNS -an inevitable consequence of BBB disruption- whose entry precedes and promotes new lesion formation. Fibrinogen is a soluble blood protein known for its role in coagulation, through its rapid conversion to fibrin, the foundation of blood clots1, 3. Analyses in human MS tissue and in several animal models identified fibrinogen in the CNS prior to leukocyte infiltration, and the onset of demyelination, or clinical symptoms. Moreover, extensive preclinical studies demonstrated that fibrinogen is unique among other blood proteins or coagulation factors that may also enter the CNS, as it promotes inflammatory processes within perivascular lesions, and thereby contributes to neuronal damage, and inhibits tissue repair processes.

20 May 2021 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
YZYufan Zheng
Yufan Zheng
JDJessica Dudman
Jessica Dudman
JCJacqueline T Chen
Jacqueline T Chen
KMKedar R Mahajan
Kedar R Mahajan
DHDanielle Herman
Danielle Herman
KNKunio Nakamura
Kunio Nakamura
Detecting cortical demyelination using magnetic resonance imaging (MRI) in multiple sclerosis (MS) remains a challenge. Magnetization transfer ratio (MTR), T1-weighted/T2-weighted ratio (T1T2R), and T2-weighted (T2w) signal are sensitive to cortical demyelination, but their accuracy is unknown. To quantify the sensitivity, specificity, and accuracy of postmortem T1T2R, MTR, and T2w in detecting cortical demyelination. In situ postmortem MRIs from 9 patients were used to measure T1T2R, MTR, and T2w along the midline of cortical gray matter and classified as normal or abnormal. MRIs were co-registered and compared to hemispheric myelin staining. The sensitivity, specificity, and accuracy of T1T2R, MTR, and T2w in detecting cortical demyelination were measured. The mean age (standard deviation) at death was 64.7 (+/-13.7) years with a disease duration of 23.8 (+/-10.5) years. The sensitivity was 78% for MTR, 75% for T1T2R, and 63% for T2w. The specificity was 46% (T2w), 13% (T1T2R), and 29% (MTR). The accuracy was 71% (T2w), 39% (MTR), and 42% (T1T2R). There were no significant differences between different MRI measures in cortical demyelination or intracortical/subpial lesion detection. Although somewhat sensitive, the modest specificity of conventional MRI modalities for cortical demyelination indicates that they are influenced by cortical changes other than demyelination. Improved acquisition and post-processing are needed to reliably measure cortical lesion load.